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VAPB/ALS8 interacts with FFAT-like proteins
including the p97 cofactor FAF1 and the ASNA1
ATPase
Yorann Baron, Patrick G Pedrioli, Kshitiz Tyagi, Clare Johnson, Nicola T Wood, Daniel Fountaine,
Melanie Wightman and Gabriela Alexandru*
Abstract
Background: FAF1 is a ubiquitin-binding adaptor for the p97 ATPase and belongs to the UBA-UBX family of p97
cofactors. p97 converts the energy derived from ATP hydrolysis into conformational changes of the p97 hexamer,
which allows the dissociation of its targets from cellular structures or from larger protein complexes to facilitate
their ubiquitin-dependent degradation. VAPB and the related protein VAPA form homo- and heterodimers that are
anchored in the endoplasmic reticulum membrane and can interact with protein partners carrying a FFAT motif.
Mutations in either VAPB or p97 can cause amyotrophic lateral sclerosis, a neurodegenerative disorder that affects
upper and lower motor neurons.
Results: We show that FAF1 contains a non-canonical FFAT motif that allows it to interact directly with the MSP
domain of VAPB and, thereby, to mediate VAPB interaction with p97. This finding establishes a link between two
proteins that can cause amyotrophic lateral sclerosis when mutated, VAPB/ALS8 and p97/ALS14. Subsequently, we
identified a similar FFAT-like motif in the ASNA1 subunit of the transmembrane-domain recognition complex (TRC),
which in turn mediates ASNA1 interaction with the MSP domain of VAPB.
Proteasome inhibition leads to the accumulation of ubiquitinated species in VAPB immunoprecipitates and this
correlates with an increase in FAF1 and p97 binding. We found that VAPB interaction with ubiquitinated proteins is
strongly reduced in cells treated with FAF1 siRNA. Our efforts to determine the identity of the ubiquitinated targets
common to VAPB and FAF1 led to the identification of RPN2, a subunit of an oligosaccharyl-transferase located at
the endoplasmic reticulum, which may be regulated by ubiquitin-mediated degradation.
Conclusions: The FFAT-like motifs we identified in FAF1 and ASNA1 demonstrate that sequences containing a
single phenylalanine residue with the consensus (D/E)(D/E)FEDAx(D/E) are also proficient to mediate interaction
with VAPB.
Our findings indicate that the repertoire of VAPB interactors is more diverse than previously anticipated and link
VAPB to the function of ATPase complexes such as p97/FAF1 and ASNA1/TRC.
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Background
FAF1 (also known as UBXN3A or UBXD12) is a p97
cofactor from the UBX-domain family. Humans express
13 UBX-domain proteins, most of which interact with
the p97 ATPase via their C-terminal UBX-domain [1,2].
Exceptionally, UBXD1 does not interact with the p97
N-terminus via its UBX domain, but uses its PUB do-
main to bind the C-terminus of p97 [3,4]. Five of these
cofactors, including FAF1, have been termed UBA-UBX
proteins due to the presence of a ubiquitin-associated
(UBA) domain at their N-terminus, which mediates inter-
action with ubiquitinated proteins. The general function
of UBA-UBX proteins is that of ubiquitin-binding
adaptors for the p97 ATPase [1,5-8]. Furthermore, three
UBA-UBX proteins – UBXD7 (or UBXN7), UBXD8 (also
known as UBXN3B, FAF2 or ETEA) and FAF1 – all have
a central UAS domain, which was recently shown to inter-
act with long-chain unsaturated fatty acids thereby me-
diating UBA-UBX protein oligomerization [9]. However,
the various UBA-UBX proteins are not functionally re-
dundant, due, at least in part, to the presence of specific
domains that are found in a single UBA-UBX protein. For
example, the UIM domain, which is only present in
UBXD7, allows this protein to interact specifically with
the NEDD8 modification on cullins [10,11]. Owing to
their ATPase activity, p97 complexes function as ‘segre-
gases’, which can dissociate their targets from protein part-
ners [12,13] or even retrotranslocate proteins from the
endoplasmic reticulum (ER) back into the cytosol to allow
for their ubiquitination and degradation [14,15]. This lat-
ter function is fundamental for p97’s role in ER-associated
degradation (ERAD), a quality control pathway that en-
sures degradation of ER proteins that are misfolded or
misassembled [16].
Vesicle-associated proteins (VAP) are highly conserved
across eukaryotes, from yeast to mammals [17-23].
Humans express two VAP proteins, VAPA and VAPB,
whose primary sequence is 63% identical. Both are
membrane-anchored at the ER and Golgi via C-terminal
transmembrane domains [20,22] and can exist as homo-
or heterodimers [18]. Oligomerization is largely mediated
by a cytoplasmic coiled-coil region, with some contribu-
tion from the transmembrane domain [24,25]. VAP pro-
teins contain an MSP domain in their N-terminal half,
which has been shown to interact with proteins containing
a FFAT motif (two phenylalanines in an acidic tract
motif ), such as members of the oxysterol-binding protein
(OSBP) family or the phosphatidylinositol transfer pro-
teins from the PITPNM family [26]. The consensus se-
quence for the FFAT motif is EFFDAxE, with an acidic
tract immediately upstream of it [27]. The crystal struc-
ture of the MSP domain bound to a FFAT peptide sug-
gests that a VAP dimer may bind two FFAT motifs, with
the FFATs engaging each other and both MSP domains of
the dimer [28].
A Phe56 to Ser mutation in the MSP domain of VAPB
causes amyotrophic lateral sclerosis (ALS) type 8 in
humans, transmitted in an autosomally dominant man-
ner [29]. Subsequently, another VAPB mutation in the
same region (Thr46 to Ile) was identified in a British
ALS patient [30]. ALS is a progressive neurodegenerative
disorder, which affects upper and lower motor neurons
and is lethal within 5 years of clinical onset [31]. Inte-
restingly, in some cases mutations in p97 can also cause
ALS [32,33].
Our mass spectrometry analysis of Flag-FAF1 immuno-
precipitates led to the identification of VAPA and VAPB
as potential interaction partners for FAF1. Given the
implication of both VAPB and p97 in ALS, we decided to
follow up on this interaction, aiming to understand
whether FAF1 might link VAPB and p97 in a common
functional pathway. We show that VAPB interaction with
FAF1 is not mediated by ubiquitin-modification of VAPB,
but it is due to the presence of a FFAT-like motif in FAF1.
Further work identified a very similar FFAT-like motif in
ASNA1, which we demonstrate is another novel binding
partner for VAPB. Although VAPB itself is not a ubiquiti-
nated target for FAF1/p97, we found that VAPB does
interact with ubiquitinated proteins in a FAF1-dependent
manner and, subsequently, identified RPN2 as a common
ubiquitinated target for VAPB and FAF1.
Results
FAF1 interacts with VAPA and VAPB
Both VAPA and VAPB were identified by mass spectrom-
etry in Flag-FAF1 immunoprecipitates from human U2OS
cells (Table 1, Additional file 1: Table S1). We first sought
to confirm these interactions by Western blotting. Indeed,
VAPA and VAPB were detected in Flag-FAF1 immuno-
precipitates from U2OS cells, using specific antibodies
(Figure 1A). Conversely, both FAF1 and p97 were present
in Flag-VAPA and Flag-VAPB immunoprecipitates from
Table 1 VAPA and VAPB were identified by mass spectrometry in Flag-FAF1 immunoprecipitates
Protein name UniProt ID MW (Da) Share of spectrum IDsa Sequence coverage
VAPA Q9P0L0 27,893 0.62% 63.9%
VAPB O95292 27,228 0.75% 65.0%
aThe share of spectrum IDs is indicated as a measure of protein abundance in the immunoprecipitates. Its value represents the percentage of peptide spectra
assigned to VAPA/B out of all identified spectra. MW, molecular weight.
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U2OS cells (Figure 1B). Next, we showed that Flag-VAPB
interaction with p97 is drastically reduced in cells treated
with FAF1 siRNA (Figure 1C, compare lanes 9 and 10
with 6 and 7). In contrast, treatment with p97 siRNA had
little, if any, effect on FAF1 binding to Flag-VAPB
(Figure 1C, lane 8). We therefore conclude that p97
binding to VAPB is mediated by FAF1.
To verify that FAF1 and VAPB also interact at endo-
genous levels, we raised rabbit antibodies to VAPB and
performed an immunoprecipitation from mouse brain
extracts. As shown in Figure 1D, endogenous VAPB in-
teracts with FAF1 and p97 in the brain. Reciprocally,
endogenous FAF1 co-immunoprecipitated VAPB from
U2OS cells (Figure 1E). Furthermore, we showed using
immunofluorescence microscopy that both VAPB and
Flag-FAF1 exhibit a punctate cytoplasmic staining and
they are co-localized, most notably in the peri-nuclear
region in a pattern typical for ER proteins (Figure 1F).
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Figure 1 FAF1 interacts with VAPA and VAPB. (A) Flag-FAF1 immunoprecipitated from U2OS cells interacts with p97, VAPA and VAPB.
(B) Flag-VAPA/B immunoprecipitated from U2OS cells interact with p97 and FAF1. (C) VAPB interaction with p97 is dependent on FAF1. U2OS cells
were treated with the indicated siRNA oligos; luciferase (Luc) siRNA was used as a control. Flag-VAPB was immunoprecipitated and immunoblots
of the immunoprecipitates (right) show that FAF1 depletion reduces the interaction with p97 whereas p97 depletion does not significantly affect
the interaction with FAF1. (D) Endogenous VAPB interacts with p97 and FAF1 in mouse brain. Endogenous VAPB was immunoprecipitated from
mouse brain extracts using Protein A-Sepharose (PAS) beads cross-linked to anti-VAPB antibodies. Uncoupled beads were used as a control.
(E) Endogenous FAF1 interacts with VAPB in U2OS cells. The immunoprecipitation was performed using sheep anti-FAF1 antibody or sheep
immunoglobulin G (IgG) as a control and PAS beads. (F) Indirect immunofluorescence of VAPB and wild-type (WT) Flag-FAF1. U2OS cells expressing Flag-FAF1
from a tetracycline-inducible promoter were grown in the presence of 200 ng/ml tetracycline for 24 hr and treated with 10 μM MG132 for
2 hr. Flag-FAF1 WT (red) co-localizes with VAPB (green) in a peri-nuclear area (enlarged window), suggesting an ER pattern. Scale bar is 10 μm.
(G) VAPB levels and its interaction with Flag-FAF1 are not affected upon proteasome inhibition. Flag-FAF1 was immunoprecipitated from U2OS
cells treated with 10 μM MG132 for 2 hr, 5 μM MG132 for 6 hr or left untreated (0 hr). Ubiquitinated proteins, p97 and VAPB were detected by
immunoblotting in inputs (left) and immunoprecipitates (right). DAPI, 4',6-diamidino-2-phenylindole; IgG, immunoglobulin G; IP, immunoprecipitate;
Luc, luciferase; WT, wild type.
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VAPB is not targeted for ubiquitin-mediated degradation
Because FAF1 is a ubiquitin-binding adaptor for the p97
ATPase [1], we initially assumed that VAPB might be
targeted for proteasomal degradation and interact with
FAF1 in its ubiquitinated form. However, we found that
proteasome inhibition with MG132 for 2 or 6 hr had no
effect on VAPB levels (Figure 1G, left panel), nor could
we detect ubiquitinated forms of VAPB even after a long
exposure of Flag-VAPB immunoprecipitates (Additional file
2: Figure S1). Moreover, VAPB interaction with Flag-FAF1
was not affected by MG132 treatment although we could
detect an increased binding of ubiquitinated proteins to
FAF1 (Figure 1G, right panel). These data suggested that
VAPB is not targeted for ubiquitin-mediated proteaso-
mal degradation. Hence, VAPB interaction with FAF1
and p97 appears to serve a function other than facilitat-
ing VAPB degradation.
FAF1 interaction with VAPB is mediated by a FFAT-like
sequence in FAF1 and the MSP domain of VAPB
To better understand the interaction of VAPB with
FAF1, we tried to map the interaction domains in both
proteins. Our task was very simple as far as VAPB is
concerned. The N-terminal half of VAPB comprises an
MSP domain, followed by a coiled-coil region and the
transmembrane region at the extreme C-terminus. Upon
over-expression in human cells, we found that the MSP
domain alone was as competent in interacting with
FAF1 and p97 as full-length VAPB (Figure 2A, right
panel). In contrast, the C-terminal region of VAPB did
not interact with FAF1/p97 at all.
Mapping the interaction region in FAF1 turned out to
be more challenging. The domain architecture of FAF1
comprises a UBA domain at the N-terminus, which
mediates the interaction with ubiquitin, followed by two
ubiquitin-like (UBL) domains, a UAS domain and the
UBX domain at the C-terminus, which mediates inter-
action with p97 (Figure 2B, top panel). We expressed in
human cells N-terminally Flag-tagged truncated versions
of FAF1 lacking the UBA domain, the two UBLs, or the
UAS and also FAF1 carrying a point mutation in the
UBX domain (Pro620 to Gly). As expected, UBA dele-
tion abolished ubiquitin binding and the P620G muta-
tion abolished p97 binding. However, to our surprise, all
these FAF1 variants had wild-type ability to interact with
VAPB (Figure 2B, right panel).
Because the MSP domain of VAPB is known to inter-
act with various proteins carrying a FFAT motif [26], we
searched the FAF1 sequence for the presence of such a
motif. There was no typical FFAT motif in FAF1. Yet in
the region between the two UBLs and the UAS domain,
we identified a short sequence that highly resembled
FFAT motifs, the main difference being that in FAF1
the second phenylalanine residue is replaced by an
additional acidic residue (Figure 2C). We therefore
tested whether deletion of the FFAT-like region in FAF1
has any effect on VAPB binding. Indeed, the removal of
only nine amino acids from residue 293 to 301 resulted
in a complete loss of VAPB binding, while p97 and ubi-
quitinated protein binding remained unaffected (Fig-
ure 2B, lane 10). To exclude the possibility that this
short truncation might affect FAF1 folding, we went on
to create a triple mutant (DFE to AAA) and three individ-
ual point mutants in that region – D295A, F296A and
E297A. Both the triple mutant and the F296A mutation
abolished VAPB binding, while the other two point mu-
tants retained the wild-type ability to interact with VAPB
(Figure 2D). We therefore conclude that FAF1 interacts
with VAPB via a highly conserved FFAT-like motif (Fig-
ure 2C), with the single phenylalanine residue present in
this region being particularly important for the
interaction.
VAPB directly interacts with FAF1 in vitro and the
interaction is not affected by the mutation causing
amyotrophic lateral sclerosis
Next, we checked whether recombinant VAPB and FAF1
could interact when mixed together in vitro. We
expressed in bacteria full-length Flag-tagged FAF1 and a
truncated version of VAPB lacking the C-terminal trans-
membrane region. Using anti-Flag beads, we were able to
isolate both Flag-FAF1 and VAPB (Figure 3A), suggesting
that VAPB interacts directly with FAF1 and does not
require additional cofactors.
The P56S mutation in VAPB that was identified in ALS
patients causes the protein to aggregate and to become in-
soluble when expressed in mammalian cells in culture
[34]. Due to the difficulty of extracting VAPB P56S from
human cells, it was not possible for us to study how this
mutation might affect FAF1 binding in human cells. How-
ever, we found that both wild-type and VAPB P56S can be
readily expressed in bacteria. Recombinant VAPB P56S
retained the wild-type ability to interact with Flag-FAF1
in vitro (Figure 3B). In contrast, a VAPB double mutant
known to be defective in FFAT binding, K87D M89D [28],
could not be co-immunoprecipitated with FAF1 under the
same conditions. These results indicate that the P56S
mutation as such does not perturb VAPB interaction with
FAF1.
VAPB interaction with FAF1 and p97 is stimulated upon
proteasome inhibition
As indicated above, VAPB did not appear to be targeted
for proteasomal degradation. However, upon Flag-VAPB
immunoprecipitation from human cells expressing VAPB
from a tetracycline-inducible promoter, we found that
VAPB interacted with ubiquitinated proteins and the
interaction was stimulated upon proteasome inhibition
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with MG132 (Figure 4A). Interestingly, proteasome inhi-
bition also stimulated VAPB interaction with FAF1 and
p97 (Figure 4A). Similar results were obtained when we
immunoprecipitated endogenous VAPB using specific an-
tibodies (Figure 4B). These data suggested that although
VAPB is not a proteasome target itself, it can interact with
proteins that are ubiquitinated and destined for prote-
asome-mediated degradation.
Because ubiquitin and FAF1 binding to VAPB appeared
to correlate, and because FAF1 is a ubiquitin-binding pro-
tein, we next tested whether FAF1 was required for VAPB
interaction with ubiquitinated proteins. We found that the
binding of ubiquitinated proteins was strongly reduced in
Flag-VAPB immunoprecipitates from cells treated with
four independent siRNA oligos for FAF1 compared to
cells treated with no siRNA or luciferase siRNA (Figure 4C).
Similarly, the binding of ubiquitinated proteins to
endogenous VAPB was reduced upon FAF1 depletion
(Figure 4D). These data suggest that FAF1 might facili-
tate, at least in part, the binding of ubiquitinated pro-
teins to VAPB. Furthermore, the VAPB double mutant
K87D M89D (KM-DD) as well as the truncated form of
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Figure 2 A FFAT-like motif mediates FAF1 interaction with VAPB. (A) The MSP domain of VAPB mediates its interaction with FAF1. Top panel:
Schematic representation of the Flag-VAPB constructs, full length (1 to 243) or truncated, C-terminal half (125 to 243) and the MSP domain N-terminal
half (1 to 125), immunoprecipitated from U2OS cells as shown in the bottom panel. Immunoblots of inputs (left) and immunoprecipitates (right) show
that the MSP of VAPB is sufficient for the interaction with FAF1/p97. A highly conserved FFAT-like motif in FAF1 mediates its interaction with VAPB.
(B) Top panel: Schematic representation of human FAF1 highlighting its various domains. Bottom panel: Wild-type or mutant variants of Flag-FAF1
were immunoprecipitated from U2OS cells. The indicated proteins were detected using specific antibodies in the inputs (left) and immunoprecipitates
(right). UBA deletion caused a dramatic reduction in ubiquitinated protein binding to FAF1 whereas a point mutation in the UBX domain (P620G)
abolished p97 binding. Deletion of the residues 293 to 301 was the only truncation that prevented VAPB binding to FAF1. (C) Alignment of FAF1
sequence from various species showing that the FFAT-like motif is highly conserved. (D) As in (B), showing that either a triple mutation D295A/F296A/
E297A or single F296A mutation in FAF1 abolished VAPB binding. IP, immunoprecipitate; WT, wild type.
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VAPB lacking the MSP domain (C-Ter) are not only de-
fective in FFAT and FAF1 binding, but also in ubiquitin
binding (Figure 4E). These VAPB variants seem to pref-
erentially bind proteins carrying shorter ubiquitin chains
than wild-type VAPB, raising the interesting possibility
that FAF1 might, in fact, be required to protect the ubi-
quitin chains from deubiquitinating enzymes or from
premature degradation. For comparison, we include a
long exposure of a Flag Western blot to demonstrate
that the different pattern observed in the ubiquitin blot
is not due to differences in the migration of Flag-VAPB
itself. The prominent band that can be detected half way
between 50 and 75 kDa upon long exposure of anti-Flag
blots, we presume to represent VAPB dimers that resist
SDS denaturation.
Mass spectrometry analysis of VAPB immunoprecipitates
reveals VAPB interaction with the TRC subunits
In an attempt to identify the ubiquitinated proteins that
interact with VAPB, we used the stable isotope labeling by
amino acids in cell culture (SILAC) technique of mass
spectrometry on endogenous VAPB immunoprecipitates
to search for proteins that accumulate after 2 and 6 hr of
proteasome inhibition with MG132. As expected, several
OSBPs and other FFAT proteins were identified in VAPB
immunoprecipitates, but their light/heavy SILAC ratios
were often close to 1 and did not follow a pattern con-
sistent with accumulation in the MG132 treated samples,
i.e. ratios higher than 1 when the light samples were
treated with MG132 and ratios lower than 1 when
the heavy samples were treated with MG132 (Additional
file 3: Table S2 and Additional file 4: Table S3). Hence,
their binding to VAPB appeared to be unaffected by prote-
asome inhibition. In general, we noticed that proteasome
inhibition caused only a mild accumulation of some
VAPB-interacting partners, with ratios mostly below two-
fold. Among these, our attention was drawn to the
four subunits of the TRC – ASNA1, BAG6, UBL4A and
GET4 – that were all present in VAPB immunoprecipi-
tates and followed a similar trend of slightly accumulating
upon proteasome inhibition (Table 2, Additional file 4:
Table S3). Our interest was further strengthened by the
observation that all four TRC subunits were also identified
by mass spectrometry in Flag-FAF1 immunoprecipitates
(Table 3, Additional file 5: Table S4). One subunit in
particular, ASNA1 (also known as TRC40 or GET3), ap-
peared to be more abundant in Flag-FAF1 immunoprecip-
itates from cells treated with MG132. Hence, we went on
to evaluate ASNA1 as a potential ubiquitinated target that
VAPB and FAF1 might have in common.
ASNA1 is a novel FFAT-like binding partner of VAPB
To begin with, we confirmed by Western blotting that
ASNA1 is present in Flag-VAPB (Figure 4A) and endogen-
ous VAPB immunoprecipitates from human cells (Figure 4B).
Consistent with the SILAC mass spectrometry results, we
F
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interacts directly with VAPB. Top panel: Schematic representation of the truncated version of VAPB (residues 1 to 210), lacking the C-terminal
transmembrane region, and Flag-FAF1 full-length proteins expressed in bacteria. Bottom panel: Immunoblots of the indicated proteins in input
extracts and anti-Flag immunoprecipitates. (B) The wild-type and the P56S mutant of VAPB (1 to 210), but not the K87D M89D double mutant,
interact with Flag-FAF1 (right panel). IP, immunoprecipitate; WT, wild type.
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Figure 4 VAPB interaction with FAF1 and p97 is stimulated upon proteasome inhibition. (A) Proteasome inhibition enhances ubiquitin, p97 and
FAF1 binding to Flag-VAPB, while ASNA1 binding remains largely unchanged. U2OS cells expressing Flag-VAPB from a tetracycline-inducible promoter were
grown in the presence of 100 ng/ml tetracycline for 24 hr or left untreated as a control. Flag-VAPB was immunoprecipitated using anti-Flag beads. (B) Prote-
asome inhibition enhances ubiquitin, p97 and FAF1 binding to endogenous VAPB, while ASNA1 binding was only slightly increased. Endogenous VAPB was
immunoprecipitated from U2OS cells using anti-VAPB antibodies cross-linked to Protein A-beads. Uncoupled beads were used as control. (C, D) The binding
of ubiquitinated proteins to VAPB is largely mediated by FAF1. U2OS cells were treated with the indicated siRNA oligos. Flag-VAPB (C) or endogenous VAPB
(D) were immunoprecipitated as described above. Depletion of FAF1 strongly reduces the binding of ubiquitinated proteins to Flag- or endogenous VAPB.
(E) The K87D M89D double mutant (KM-DD) of VAPB is defective in p97, FAF1, ASNA1 and ubiquitin binding. Flag-VAPB full-length WT, KM-DD and trun-
cated, C-terminal half (C-Ter) and N-terminal half (MSP), were immunoprecipitated from U2OS cells. The MSP domain of VAPB is sufficient to interact with
p97, FAF1 and ASNA1. KM-DD as well as the truncation lacking the MSP domain (C-Ter) are defective in binding poly-ubiquitinated proteins and seem to
interact preferentially with oligo-ubiquitinated proteins. (F) The binding of ubiquitinated proteins to VAPB is reduced in cells treated with ASNA1 siRNA.
U2OS cells expressing Flag-VAPB from a tetracycline-inducible promoter were treated with the indicated siRNA oligos. Depletion of ASNA1 reduces ubiquitin
and BAG6 binding, but not FAF1 binding, to Flag-VAPB. C-Ter, C-terminal half; IP, immunoprecipitate; KM-DD, K87D M89D double mutant; Luc, luciferase.
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observed a very mild increase in ASNA1 binding to
endogenous VAPB upon MG132 treatment (Figure 4B).
No such change could be observed in Flag-VAPB immu-
noprecipitates (Figure 4A). Moreover, ASNA1 levels did
not change upon proteasome inhibition (Figure 4A,B,
left panels). Taken together, these data suggested that
ASNA1 may not be itself a proteasome target. However,
because ASNA1 interaction with VAPB was fairly robust,
we proceeded to search for a potential FFAT motif in
any of the TRC subunits that could mediate a direct
interaction with VAPB. This led to the identification of a
FFAT-like sequence close to the N-terminus of ASNA1
that was very similar to the one we uncovered in FAF1
(Figure 5A). As seen before for FAF1, this region of
ASNA1 is well conserved across species (Figure 5B). In-
deed, mutating the phenylalanine residue (Phe15 to Ala)
in this putative FFAT motif abolished Flag-ASNA1 inter-
action with VAPB (Figure 5C). Reciprocally, the VAPB
double mutant (K87D M89D) that is defective in FFAT
binding was unable to interact with ASNA1 (Figure 4E).
Like FAF1, ASNA1 interacts efficiently with the MSP
domain, but not with the C-terminal region of VAPB
(Figure 4E). We conclude that ASNA1 interacts with the
MSP domain of VAPB via a FFAT-like motif similar to
FAF1. As seen before for FAF1, Flag-ASNA1 co-localization
with endogenous VAPB is most prominent in the peri-
nuclear region (Figure 5D).
Because the TRC complex has been implicated in ubi-
quitin-dependent degradation of mislocalized ER mem-
brane proteins [35], we also checked if ASNA1 might
contribute to the binding of ubiquitinated proteins to
VAPB. As shown in Figure 4F, ASNA1 depletion by
siRNA leads to a reduction in Flag-VAPB interaction
with ubiquitinated proteins. We conclude that part of
the ubiquitinated targets that interact with VAPB could
be TRC quality control targets that are recruited via
ASNA1.
FAF1 interaction with ASNA1 depends on the UBA
domain
Next we wanted to verify whether ASNA1 also interacts
with FAF1 as suggested by the mass spectrometry
analysis (Table 3). Unlike ASNA1 interaction with VAPB,
its interaction with Flag-FAF1 was weak and hard to
detect in the absence of proteasome inhibition (Figure 5E,
lanes 2 to 7). Upon proteasome inhibition, ASNA1
interaction with Flag-FAF1 became readily detectable
(Figure 5E, lanes 9 to 14) and it required the UBA domain
of FAF1 (Figure 5E, lane 10). Conversely, Flag-ASNA1
interaction with endogenous FAF1 was only detectable
upon proteasome inhibition, which also caused a consid-
erable increase in the binding of ubiquitinated proteins to
ASNA1 (Figure 5F, compare lanes 2 and 7). Interestingly,
ASNA1 interaction with FAF1 did not depend on the
ASNA1 FFAT-motif (Figure 5F, lane 10), but was drastic-
ally reduced by a Gly46 point mutation in ASNA1 to
either Ala or Arg (Figure 5F, lanes 8 and 9) [36]. We found
that these two mutants are completely defective in inter-
acting with the BAG6 subunit of the TRC complex
and exhibit reduced binding to ubiquitinated proteins
(Figure 5F). Taken together, these findings indicate a
correlation between the binding of ubiquitinated proteins
to ASNA1 and a detectable interaction with FAF1. They
suggest that FAF1 binding to ASNA1 is likely indirect and
mediated by the ubiquitinated proteins that associate with
ASNA1.
Table 2 TRC complex subunits slightly accumulate in endogenous VAPB immunoprecipitates upon proteasome
inhibition
Protein
name
UniProt
ID
MW
(Da)
SILAC ratio L/Ha
L +MG 2 hr H +MG 2 hr L +MG 6 hr H +MG 6 hr
ASNA1 O43681 38,793 1.31 ± 0.08 (31) 0.79 ± 0.07 (27) 1.42 ± 0.10 (32) 0.87 ± 0.06 (35)
BAG6 P46379 119,409 1.47 ± 0.18 (36) 0.77 ± 0.11 (36) 1.43 ± 0.19 (52) 0.94 ± 0.10 (43)
GET4 Q7L5D6 36,504 1.39 ± 0.11 (8) 0.73 ± 0.06 (11) 1.30 ± 0.08 (9) 0.84 ± 0.03 (13)
UBL4A P11441 17,777 1.50 ± 0.10 (7) 0.74 ± 0.04 (9) 1.51 ± 0.15 (7) 0.89 ± 0.04 (10)
aLight- (L) and heavy-labeled (H) cells were treated with MG132 (MG) for 2 or 6 hr, as indicated. Equal amounts of light- and heavy-labeled extracts were mixed
and endogenous VAPB was immunoprecipitated using specific antibodies. The light/heavy SILAC ratios (L/H) determined by mass spectrometry are indicated.
L +MG indicates that the light-labeled samples were treated with MG132. Proteins whose interaction with VAPB is stimulated by proteasome inhibition accumulate
in these samples, resulting in L/H ratios higher than 1. H +MG indicates that the heavy-labeled samples were treated with MG132. Protein accumulation in the
heavy-labeled samples results in L/H ratios lower than 1. The L/H for proteins that are not affected by proteasome inhibition will be close to 1. The numbers in
parenthesis represent the number of spectra analyzed for each sample.
Table 3 TRC subunits were identified by mass
spectrometry in Flag-FAF1 immunoprecipitates
Protein
name
UniProt
ID
MW
(Da)
Share of spectrum IDsa
No MG MG 2 hr MG 6 hr
ASNA1 O43681 38,793 0.11% 0.30% 0.18%
BAG6 P46379 119,409 0.50% 0.56% 0.49%
GET4 Q7L5D6 36,504 0.05% 0.10% 0.08%
UBL4A P11441 17,777 0.11% 0.13% 0.08%
aFlag-FAF1 was immunoprecipitated from U2OS cells treated with MG132 (MG)
for 0, 2 or 6 hr as indicated. The share of spectrum IDs is indicated as a
measure of protein abundance in the immunoprecipitates.
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RPN2 is a common ubiquitinated target for VAPB and
FAF1
Because our SILAC mass spectrometry analysis of en-
dogenous VAPB immunoprecipitates did not reveal any
protein that would significantly accumulate upon pro-
teasome inhibition, we reasoned that the ubiquitinated
targets of VAPB might be present at very low levels in
the immunoprecipitates and escape our analysis. To
overcome this limitation, we decided to enrich the ubi-
quitinated peptides prior to mass spectrometry analysis
using a two-step immunoprecipitation protocol. A mix-
ture of light-labeled Flag-VAPB and heavy-labeled Flag-
FAF1 immunoprecipitates was trypsin-digested and the
peptides carrying a di-glycine signature were isolated
using antibodies specific to lysine-ε-GlyGly [37]. Di-
glycine peptides mark the site of ubiquitination in the
protein of origin. They have low abundance relative to
peptides that do not carry a GlyGly extension and they are
also harder to detect by mass spectrometry. Di-glycine
peptide enrichment using specific antibodies greatly
enhances their identification by mass spectrometry and
unequivocally demonstrates which proteins identified in
our immunoprecipitates were modified with ubiquitin. To
specifically identify ubiquitinated targets common for
VAPB and FAF1, the list of ubiquitinated proteins ob-
tained from the mass spectrometry analysis of di-glycine
peptides was cross-referenced with proteins we previously
identified by mass spectrometry in both Flag-VAPB and
Flag-FAF1 immunoprecipitates (Additional file 6: Table
S5). This revealed two potentially interesting targets, the
RPN2 and DDOST subunits of the N-oligosaccharyl-
transferase (Table 4), which, like VAPB, are localized at
the ER. Both proteins appeared to accumulate slightly in
endogenous VAPB immunoprecipitates upon proteasome
inhibition, as determined by SILAC mass spectrometry
(Table 5, Additional file 4: Table S3) and were identified at
low levels in Flag-FAF1 immunoprecipitates (Table 6,
Additional file 5: Table S4). We confirmed RPN2 inter-
action with Flag-VAPB and Flag-FAF1 by Western blot-
ting and found the interaction with VAPB to be more
robust (Figure 6A). There was no detectable change in
RPN2 levels upon proteasome inhibition (Figure 6A,
left panel), nor could we detect ubiquitinated forms of
RPN2 in extracts or immunoprecipitates (Figure 6A). This
suggests that only a minor fraction of RPN2 is subject to
ubiquitin-mediated proteasomal degradation. However,
we could detect a modest increase in RPN2 binding to
endogenous VAPB (Figure 6B, right panel), consistent with
the mass spectrometry results (Table 5). This supports the
notion that VAPB interacts with a fraction of RPN2 that is
destined for proteasome-mediated degradation. If RPN2
were a target for the ERAD quality control pathway, we
reasoned that artificially inducing ER stress with tunica-
mycin might stimulate RPN2 degradation and its asso-
ciation with VAPB and FAF1. We found that tunicamycin
treatment had no significant effect on RPN2 levels or its
interaction with endogenous VAPB (Figure 6C). Further-
more, tunicamycin did not stimulate VAPB interaction
with FAF1 and there was no added effect of tunicamycin
when used in combination with MG132. In contrast, an-
other glycosylated protein, CD147, shifted from the glyco-
sylated form to a faster migrating, non-glycosylated form,
indicating that the tunicamycin treatment was effective at
least to some extent (Figure 6C, left panel). We are not
certain whether our ER-stress conditions are not optimal
to affect RPN2 or RPN2 ubiquitin-dependent degradation
is part of its regulation and not a quality control process.
VAPA and VAPB interact with proposed FFAT proteins,
RAB3GAP1 and WDR44
Our mass spectrometry analysis of Flag-VAPA, Flag-VAPB
and endogenous VAPB immunoprecipitates also revealed
three binding partners for VAPA and VAPB that appeared
(See figure on previous page.)
Figure 5 ASNA1 interacts with VAPB via a FFAT-like motif similar to FAF1. (A) Alignment of the FFAT-like motifs in human ASNA1 and
FAF1. (B) Alignment of the FFAT-like motif of ASNA1 across species showing that it is highly conserved. (C) A point mutation in the FFAT-like
motif of ASNA1 (F15A) abolishes its interaction with VAPB. WT and mutant Flag-ASNA1 were immunoprecipitated from U2OS cells using anti-Flag
beads. (D) Indirect immunofluorescence of VAPB and Flag-ASNA1 WT. U2OS cells were transfected with Flag-ASNA1 WT for 24 hr. Flag-ASNA1 WT
(red) is co-localized with VAPB (green) in a peri-nuclear area (enlarged window) suggesting an ER pattern. Scale bar is 10 μm. (E) ASNA1 interaction
with FAF1 is strongly stimulated upon proteasome inhibition with MG132 and depends on the UBA domain. WT Flag-FAF1 and the indicated mutants
were immunoprecipitated from U2OS cells. (F) G46R and G46A point mutations in ASNA1 abolish its interaction with BAG6 and strongly reduce its
interaction with FAF1 and ubiquitin, most noticeably after MG132 treatment, but do not affect the interaction with VAPB. WT and mutant Flag-ASNA1
were immunoprecipitated from SH-SY5Y cells. DAPI, 4',6-diamidino-2-phenylindole; IP, immunoprecipitate; WT, wild type.
Table 4 Ubiquitinated targets of VAPB and FAF1 identified
by mass spectrometry upon enrichment of ubiquitinated
peptides
Protein name UniProt ID GlyGly peptidesa (times identified)b
RPN2 P04844 LSK154EETVLATVQALQTASHLSQQADLR (4×)
K244NFESLSEAFSVASAAAVLSHNR (2×)
LHNQK442TGQEVVFVAEPDNK (3×)
DDOST P39656 APTIVGK189SSLNPILFR (2×)
aA mixture of light-labeled Flag-VAPB and heavy-labeled Flag-FAF1
immunoprecipitates was analyzed by mass spectrometry after ubiquitinated peptide
enrichment using antibodies specific to lysine-ε-GlyGly. The lysine residues carrying
the GlyGly modification are indicated in bold and the superscript is the position in
the protein sequence.
bThe numbers in parenthesis indicate how many times each peptide was
identified by mass spectrometry.
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to be very abundant, especially in Flag immunoprecipi-
tates. These were RAB3GAP1, RAB3GAP2 and WDR44
(Table 7, Additional file 7: Table S6, Additional file 8:
Table S7 and Additional file 9: Table S8). RAB3GAP1 and
2 form a GTPase activating complex for RAB3 proteins
[38,39], which are expressed specifically in the brain and
regulate neurotransmitter release [40]. First, we set out to
confirm these interactions by Western blotting. Indeed,
Flag-VAPB expressed in HeLa cells co-immunoprecipi-
tated RAB3GAP1 and 2, as well as WDR44 (Figure 7A).
Furthermore, endogenous VAPB from mouse brain co-
immunoprecipitated RAB3GAP1 (Figure 7B) as well as
WDR44 and ASNA1 (Figure 7C), suggesting that these
interactions could be relevant for VAPB function in the
brain. The seemingly strong interaction these proteins
exhibited with VAPA and VAPB prompted us to have a
closer look at their primary sequence to check if they
might harbor a FFAT motif. There was no such motif in
RAB3GAP2, but RAB3GAP1 did contain a short sequence
that partly resembled a FFAT motif (Figure 7D). Mutating
both phenylalanine residues to alanine fully prevented
Flag-RAB3GAP1 interaction with VAPB and had no effect
on its interaction with RAB3GAP2 (Figure 7D). We
conclude that, although non-canonical, the short motif
present in RAB3GAP1 is a bona fide FFAT motif in that
it mediates the interaction with VAPA/B. WDR44, on
the other hand, contained a putative FFAT motif that
closely resembled those found in OSBPs (Additional file
3: Table S2) and was located close to the N-terminus of
the protein. A truncated version of WDR44 lacking the
first 15 amino acids was unable to interact with VAPB
(Figure 7E), confirming that this was the region that
mediated VAPB binding. Furthermore, we showed that
the VAPB double mutant defective in FFAT binding
(K87D M89D) was not only defective in FAF1 binding,
but was also unable to interact with RAB3GAP1 or
WDR44 (Figure 7F, compare lanes 7 and 8). Hence, we
conclude that FAF1, RAB3GAP1 and WDR44, all inter-
act in a similar manner with the MSP domain of VAPA
and VAPB.
Our analysis of VAPB immunoprecipitates from mouse
brain also revealed VAPB interaction with syntaxin 1A
and B (STX1A and B) (Table 7, Additional file 9: Table
S8, Additional file 10: Figure S2A). These proteins har-
bor a sequence that resembles a FFAT motif (Additional
file 10: Figure S2B), but mutating the two phenylalanine
residues in either STX1A or STX1B to alanine had no
effect on their interaction with VAPB (Additional file 10:
Figure S2C). Hence, these are not functional FFAT mo-
tifs and are not responsible for syntaxin 1A/B interaction
with VAPB.
Discussion
FAF1 is a FFAT-like binding partner for VAPB
Humans express five ubiquitin-binding UBX proteins,
including FAF1 and UBXD7. Previous work showed that
UBXD7 is unique among p97 cofactors due to the pres-
ence of an UIM motif that allows it to interact directly
with neddylated cullins [10,11]. Here we show that FAF1
contains an atypical FFAT motif that allows it to asso-
ciate with the membrane-anchored proteins VAPA and
VAPB. Although distinct from the consensus proposed
for FFAT motifs [27] due to the absence of a second aro-
matic residue, the FFAT motif of FAF1 is still able to
mediate the interaction with the MSP domain of VAPB.
The UIM motif of UBXD7 and the FFAT motif of
FAF1 represent features unique to each of these UBX
proteins and mediate their interaction with specific
targets, neddylated cullins and VAPA/B respectively. The
identification of these short protein-interaction motifs
supports the notion that the general function of UBA-
UBX proteins as ubiquitin-binding adaptors for p97 is
complemented with specific functions mediated by
singular motifs.
Table 5 RPN2 and DDOST slightly accumulate in endogenous VAPB immunoprecipitates upon proteasome inhibition
Protein
name
UniProt
ID
MW
(Da)
SILAC ratio L/Ha
L +MG 2 hr H +MG 2 hr L +MG 6 hr H +MG 6 hr
RPN2 P04844 69,284 1.11 ± 0.02 (4) 0.88 ± 0.00 (2) 1.30 ± 0.10 (4) 0.96 ± 0.02 (6)
DDOST P39656 50,801 - - 1.12 ± 0.00 (2) 0.64 ± 0.00 (1)
aLight- (L) or heavy-labeled (H) cells were treated with MG132 (MG) for 2 or 6 hr, as indicated. Equal amounts of light- and heavy-labeled extracts were mixed, and
endogenous VAPB was immunoprecipitated using specific antibodies. The light/heavy SILAC ratios (L/H) determined by mass spectrometry are indicated. L + MG
indicates that the light-labeled samples were treated with MG132. Proteins whose interaction with VAPB is stimulated by proteasome inhibition accumulate in
these samples, resulting in L/H ratios higher than 1. H +MG indicates that the heavy-labeled samples were treated with MG132. Protein accumulation in the
heavy-labeled samples results in L/H ratios lower than 1. The L/H for proteins that are not affected by proteasome inhibition will be close to 1. The numbers in
parenthesis represent the number of spectra analyzed for each sample.
Table 6 RPN2 and DDOST were identified at low levels in
Flag-FAF1 immunoprecipitates
Protein
name
UniProt
ID
MW
(Da)
Share of spectrum IDsa
No MG MG 2 hr MG 6 hr
RPN2 P04844 69,284 - 0.05% 0.03%
DDOST P39656 50,801 0.04% 0.05% 0.04%
aFlag-FAF1 was immunoprecipitated from U2OS cells treated with MG132 (MG)
for 0, 2 or 6 hr, as indicated. The share of spectrum IDs is indicated as a
measure of protein abundance in the immunoprecipitates.
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Figure 6 RPN2 is a common interactor of VAPB and FAF1. (A) Flag-VAPB and Flag-FAF1 were immunoprecipitated from U2OS cells treated with
10 μM MG132 for 2 hr, 5 μM MG132 for 6 hr or left untreated (0 hr). Asterisks indicate non-specific bands. (B) Proteasome inhibition enhances RPN2
binding to endogenous VAPB. Endogenous VAPB was immunoprecipitated from U2OS cells treated with 10 μM MG132 for 2 hr or left untreated (0 hr).
(C) ER stress induced by tunicamycin treatment does not affect RPN2 levels or its binding to VAPB. Endogenous VAPB was immunoprecipitated from
U2OS cells treated with 5 μg/ml tunicamycin for 5 h, 10 μM MG132 for 2 hr, both tunicamycin and MG132, or dimethyl sulfoxide as a control. DMSO,
dimethyl sulfoxide; IP, immunoprecipitate; MG, MG132.
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Identification of novel binding partners of VAPB carrying
FFAT-like sequences
The identification of a degenerated, yet functional FFAT
motif in FAF1, indicated that other proteins carrying
FFAT-like motifs could represent bona fide interaction
partners for VAPB. On one hand, non-canonical FFAT
motifs may be present in known VAPB-binding partners
and on the other hand, searching for FFAT motifs that
only partially match the consensus sequence could lead
to the identification of novel VAPB-binding partners.
We took the first approach and validated the FFAT-like
motifs in ASNA1, RAB3GAP1 and WDR44, proteins that
we identified in VAPB immunoprecipitates by mass spec-
trometry. Mikitova and Levine took the latter approach
and computationally identified multiple high-confidence
FFAT-like proteins, based on the degree of variation that
is tolerated by FFAT motifs in a yeast reporter assay [41].
RAB3GAP1 scored high as a potential binding partner for
VAPB in this study, but the more divergent FFAT-like
motifs in FAF1 and ASNA1 were not recognized.
FFAT-like motifs of WDR44 and RAB3GAP1 have
been picked out by prior computational searches
[27,28,41] and we confirm that they are functional and
truly mediate VAPB binding. Our experiments with
syntaxin 1A and B, whose FFAT-like sequences are not
required for the interaction with VAPB, further highlight
the importance of experimentally testing putative FFAT
motifs.
VAPB interacts with ubiquitinated proteins
Several observations led us to believe that VAPB itself is
not a proteasome substrate: (1) VAPB does not accumu-
late upon proteasome inhibition with MG132 (Figure 4B);
(2) anti-Flag Western blots of Flag-VAPB immunopre-
cipitates did not reveal any slower migrating, ubiquiti-
nated forms of VAPB, even after proteasome inhibition
(Additional file 2: Figure S1); (3) VAPB interaction with
FAF1 is not mediated by the ubiquitin-binding UBA
domain of FAF1 (Figure 2B), and (4) no ubiquitinated
peptide was identified for VAPB in our mass spectrometry
analysis of di-glycine peptides from Flag-VAPB/Flag-FAF1
immunoprecipitates.
Kanekura et al. previously observed ubiquitinated spe-
cies in over-expressed VAPB immunoprecipitates and
assumed them to be ubiquitinated VAPB [34]. Instead,
we present evidence for VAPB interaction with ubiquiti-
nated proteins: (1) VAPB interacts with ubiquitinated
proteins as shown by the anti-ubiquitin Western blotting
of Flag-VAPB and endogenous VAPB immunopre-
cipitates; (2) VAPB interacts directly with a ubiquitin-
binding protein, FAF1, and (3) VAPB interaction with
ubiquitin is reduced when FAF1 is depleted by treatment
with siRNA (Figure 4).
One possibility is that the direct binding of FAF1 to
VAPB mediates VAPB interaction with ubiquitinated
species that are recognized by the UBA domain of FAF1.
Alternatively, the proteins that are modified with ubiquitin
interact directly with VAPB and FAF1, which is required
to protect the ubiquitin chains from deubiquitinating
enzymes or from degradation via alternative ubiquitin
receptors. This latter possibility is strongly supported by
the observation that VAPB variants that cannot bind FFAT
proteins interact with ubiquitinated species carrying
shorter ubiquitin chains than observed for wild-type VAPB
(Figure 4E). Furthermore, RPN2, a novel ubiquitinated tar-
get we identified for VAPB and FAF1, interacts more ro-
bustly with VAPB than with FAF1 (Figure 6A), suggesting
that the interaction is unlikely to be mediated by FAF1.
FFAT-like proteins add to the complexity of VAPB
function
Most, if not all, canonical FFAT proteins identified to date
are involved in lipid metabolism. They include lipid-
binding proteins such as the OSBPs and lipid-transport
Table 7 FFAT-like proteins identified in VAPA and VAPB immunoprecipitates by mass spectrometry
Protein
name
UniProt
IDa
MW
(Da)a
FFAT
motifa
Share of spectrum IDsb
Flag-VAPA
(U2OS)
Flag-VAPB
(U2OS)
Endogenous VAPB
HeLa cells Mouse brain
FAF1 Q9UNN5 73954 DFEDATE 0.85% 0.68% 0.06% -
ASNA1 O43681 38793 EFEDAPD 0.69% 0.79% 0.20% -
RAB3GAP1 Q15042 110524 EFFECLS 2.65% 1.79% 0.20% 0.43%
RAB3GAP2 Q9H2M9 155985 NA 1.73% 1.61% 0.10% 0.37%
WDR44 Q5JSH3 101366 EFYDAPE 1.97% 1.66% - 0.05%
STX1Bc P61266 33245 EFFEQVE - - - 0.20%
STX1Ac Q16623 33023 EFFEQVE - - - 0.03%
aThe UniProt ID, MW and FFAT motif are indicated for the human proteins.
bThe share of spectrum IDs is indicated as a measure of protein abundance in the immunoprecipitates.
cSTX1A and B are shown in italics because their putative FFAT-like motifs could not be confirmed experimentally.
NA, not applicable.
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proteins such as the PITPNMs and the ceramide transfer
protein (CERT) [26]. Here we show that proteins with
slightly divergent FFAT motifs can also interact with the
MSP domain of VAPB. These novel interaction partners
add further layers of complexity to the VAPB function by
implicating VAPB in p97-regulated processes via FAF1, in
TRC complex function via ASNA1 and in RAB3 regula-
tion via RAB3GAPs.
The related FFAT motifs present in FAF1 and ASNA1
link VAPB to ATPase complexes, such as p97 and the
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Figure 7 RAB3GAP1 and WDR44 are FFAT-like interactors of VAPB. (A) Flag-VAPB immunoprecipitated from HeLa cells interacts with RAB3GAP1,
RAB3GAP2 and WDR44. The RAB3GAP1 and WDR44 interactions with VAPB are mediated by FFAT motifs. VAPB immunoprecipitation from mouse brain
extract confirms its interaction with RAB3GAP1 (B), ASNA1 and WDR44 (C). Flag-RAB3GAP1 WT and F585A/F586A (FF-AA) (D) and Flag-WDR44 WT and
Δ1-15 (E) were immunoprecipitated from U2OS cells. Both RAB3GAP1 and WDR44 contain FFAT motifs, as indicated in the top panels, which are
responsible for the interaction with VAPB. The formation of the RAB3GAP1/2 heterodimer is not affected by the mutation of the FFAT motif in RAB3GAP1.
(F) Immunoprecipitation of Flag-VAPA WT, Flag-VAPB WT or the K87D M89D mutant of VAPB from U2OS cells shows that the KM-DD mutant is defective
in interacting with RAB3GAP1 and WDR44. FF-AA, F585A/F586A; IP, immunoprecipitate.
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TRC (Figure 8A). The identification of RPN2 and DDOST
as common ubiquitinated targets for VAPB and FAF1 sug-
gests that VAPB might recruit FAF1/p97 to ubiquitinated
targets located at the ER membrane (Figure 8B). Both
RPN2 and DDOST are mostly lumenal and anchored in
the ER membrane via C-terminal transmembrane regions.
Interestingly, all the ubiquitination sites we identified in
RPN2 and DDOST are located in the lumenal region of
the proteins, highlighting the importance of the inter-
action with the p97 machinery for retrotranslocation from
the ER into the cytosol, where they would become acces-
sible to ubiquitin ligases and the proteasome.
ASNA1, on the other hand, mediates VAPB interaction
with TRC, which is required for membrane insertion of
some tail-anchored proteins [36] and also for the
elimination of mislocalized membrane proteins [35].
Interestingly, although VAPB is a tail-anchored protein,
it does not interact with the TRC via its C-terminal
transmembrane region. We show that ASNA1 interacts
only with the MSP domain of VAPB and not with the
C-terminal region, which includes the transmembrane
domain (Figure 4E). CAML and WRB were identified
to be the receptors that recruit the TRC to the ER mem-
brane for insertion of tail-anchored proteins [42,43]. We
show that ASNA1 transiently interacts with ubiquiti-
nated proteins that are targeted for proteasomal degrad-
ation and appear to recruit FAF1 (Figure 5F). Furthermore,
a fraction of the ubiquitinated proteins that interact with
VAPB are recruited via ASNA1 (Figure 4F). It is possible
that VAPB may represent an alternative receptor for TRCs
B
A
C
Figure 8 VAPB interacts with novel FFAT-like proteins, FAF1 and ASNA1. (A) The FFAT-like motif of FAF1 mediates its interaction with the
MSP domain of VAPB and recruits FAF1/p97 to the ER membrane. Similarly, the FFAT-like sequence in ASNA1 mediates VAPB interaction with the
TRC complex. (B) RPN2 is a common ubiquitinated target for FAF1 and VAPB. We propose that, on one side, FAF1 protects ubiquitinated RPN2
from deubiquitinating enzymes (DUBs) and other ubiquitin receptors and, on the other side, it recruits p97 hexamers that are necessary for
extracting misfolded or misassembled RPN2 from the ER membrane, to allow for its proteasome-mediated degradation. (C) ASNA1 mediates VAPB
interaction with a subset of ubiquitinated targets that interact with FAF1 via their ubiquitin chains. We propose that VAPB might represent an al-
ternative receptor for TRCs that are implicated in clearing mislocalized ER proteins.
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whose ubiquitinated targets require p97/FAF1 for degrad-
ation (Figure 8C).
Conclusions
Starting from the observation that the p97 cofactor
FAF1 interacts with the ER membrane proteins VAPA
and VAPB, we identified an atypical FFAT sequence in
FAF1 that allows its direct interaction with the MSP do-
main of VAPA/B. A similar FFAT-like sequence was sub-
sequently recognized in the ASNA1 subunit of the TRC,
further expanding the repertoire of proteins that interact
with VAPB in this manner. The identification of two
subunits of an ER-resident glycosyltransferase – RPN2
and DDOST – as common ubiquitinated targets for
VAPB and FAF1, suggests that VAPB might recruit p97/
FAF1 to facilitate degradation of a subset of targets
located at the ER.
Thus, VAPB dimers emerge as a platform for docking
various FFATand FFAT-like proteins at the ER membrane.
These include proteins involved in lipid metabolism as
previously noted, but also, as shown in this study, the ubi-
quitin receptor FAF1, the ASNA1 component of the TRC
that mediates/monitors protein insertion in the ER mem-
brane and regulatory enzymes such as RAB3GAP1/2. Per-
turbations in VAPB interaction with any of these proteins
when VAPB aggregates due to the ALS-causing P56S
mutation could be responsible for the defects that lead to
ALS8 disease.
Methods
Cloning information
Human FAF1 [GenBank:NM_007051.2] was amplified
from EST IMAGE 5928559. For mammalian expression,
wild-type and mutant FAF1 variants (lacking the native
methionine) were subcloned as Sal1/Not1 inserts into
pCMV5-Flag. For bacterial expression, wild-type FAF1
was subcloned into a modified pGEX6P-1 vector contai-
ning a TEV protease site and a Flag-tag downstream of
the GST. Human VAPB [GenBank:NM_004738.3] was
amplified from EST IMAGE 3543354. For mammalian
expression, wild-type, mutant and truncated variants were
subcloned as BamH1/Not1 inserts into either pCMV5-
Flag or a modified version of pcDNA5-FRT/TO contai-
ning an N-terminal Flag-tag. For bacterial expression,
ORFs were subcloned as BamH1/Not1 inserts into a
modified pGEX6P-1 vector containing a TEV protease
site, before removing extraneous linker residues between
the glutamine of the TEV and the native methionine
of VAPB by site-directed mutagenesis. Human VAPA
[GenBank:NM_003574] was amplified from EST IMAGE
4662097 and subcloned as a BamH1/Not1 insert into
pCMV5-Flag for mammalian expression. Human RAB3-
GAP1 [GenBank:NM_001172435.1] was amplified from
EST IMAGE 5276867. For mammalian expression, a silent
mutation (t909c) was first introduced to disrupt an internal
BamH1 site before subcloning as BamH1/Not1 inserts
into pcDNA5-FRT/TO-Flag. Human WDR44 [GenBank:
NM_019045.4] was amplified by RT-PCR from embryonic
umbilical RNA (Agilent Technologies, Wokingham, UK).
Human ASNA1 [GenBank:NM_004317.2] was amplified
by RT-PCR from total uterus RNA (Agilent Technologies).
Wild-type and mutant variants were subcloned as BamH1/
Not1 inserts into pCMV5-Flag for mammalian expression.
PCR reactions were carried out using KOD Hot Start
DNA Polymerase (Merck Millipore, Darmstadt, Germany).
Reverse transcriptase reactions were carried out using
Superscript III (Life Technologies). All full-length products
were cloned into pSc-B or pSc-A (Agilent Technologies,
Carlsbad, USA) and fully sequenced prior to further sub-
cloning or manipulation. All mutations and deletions were
made following the Quickchange method (Agilent Tech-
nologies), but using KOD Hot Start DNA Polymerase.
DNA sequencing was performed by the Sequencing Service
at the College of Life Sciences, University of Dundee [44].
For plasmid requests, please contact Medical Research
Council Protein Phosphorylation and Ubiquitylation Unit
(MRC-PPU) Reagents [45].
Cell culture and transfection
U2OS and HeLa cells were respectively cultured in
McCoy’s and MEM media (Gibco, Pailsey, UK) supple-
mented with 10% fetal bovine serum (FBS) (Thermo
Scientific, Fremont, USA), 2 mM L-glutamine (Invitrogen,
Camarillo, USA), 100 units/ml penicillin, 100 μg/ml
streptomycin (Invitrogen). SH-SY5Y cells were cultured in
DMEM/F12 (Gibco) supplemented with 10% FBS, 1%
NEAA (Gibco), 2 mM L-glutamine, 100 units/ml penicil-
lin, 100 μg/ml streptomycin. Then 10 μM MG132 (Enzo,
Farmingdale, USA) was added to the media for the indi-
cated time before harvesting the cells. Tunicamycin
(Sigma, Saint Louis, USA) was used at 5 μg/ml for 5 hr.
Flag-VAPB and Flag-FAF1 U2OS cells were generated
from Flp-In T-REx U2OS cells, following Invitrogen’s in-
structions and were maintained in McCoy’s media supple-
mented with 10% FBS, 2 mM L-glutamine, 100 units/ml
penicillin, 100 μg/ml streptomycin, 100 μg/ml hygromycin,
15 μg/ml blasticidin (Invitrogen). The expression of Flag-
VAPB and Flag-FAF1 was respectively induced by adding
100 ng/ml and 200 ng/ml tetracycline (Bioline, London,
UK) for 24 hr.
For SILAC mass spectrometry, low passage U2OS cells
were labelled using DMEM high-glucose media without
arginine, lysine or methionine (Biosera, Boussens, France)
reconstituted in filter-sterilized water supplemented with
3.7 g/l NaHCO3 and 10% dialyzed FBS (Biosera). The
media was supplemented with 2 mM L-glutamine, 100
units/ml penicillin, 100 μg/ml streptomycin, 30 μg/ml
methionine and respectively 146 μg/ml and 84 μg/ml of
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either lysine K0 and arginine R0 (Sigma) for light (K0R0)
labelling or lysine K8 and arginine R10 (Cambridge Iso-
tope Lab, Tewksbury, USA) for heavy (K8R10) labelling.
After two weeks of culture in SILAC DMEM, the labelling
efficiency was checked by mass spectrometry of random
peptides.
Plasmid transfections were performed using TransIT-
LT1 (Mirus, Madison, USA), following the manufacturer’s
instructions. Briefly, approximately 3 × 106 cells were cul-
tured on a 15-cm plate. Then 24 hr later, the media was
refreshed without antibiotics and the cells were trans-
fected with 10 μg plasmid for 24 hr. siRNA transfections
were performed for 48 hr, using oligos from Thermo Sci-
entific at a final concentration of 5 nM and Lipofectamine
RNAiMAX (Invitrogen) according to the manufacturer’s
instructions. The following siRNA oligos were used:
for FAF1 #0 (5′-CCACCUUCAUCAUCUAGUC-3′) [46]
and siGENOME #1 (D-009106-01), #3 (D-009106-03),
#4 (D-009106-04); for p97 (D-008727-06); for ASNA1 #3
(D-009666-03) and #18 (D-009666-18), and the Luciferase
Duplex (P-002099) as non-targeting control.
Cell extracts and immunoprecipitation
For immunoprecipitation, the cells were lysed in buffer A
(50 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic
acid (HEPES)/KOH, pH 7.2; 5 mM Mg(OAc)2; 70 mM
KOAc; 0.2% Triton X-100; 10% glycerol; 0.2 mM ethylene-
diaminetetraacetic acid (EDTA); complete protease inhi-
bitor cocktail (Roche, Mannheim, Germany). The lysates
were incubated with anti-Flag beads (Anti-Flag M2 Affin-
ity Gel, A2220, Sigma) or anti-VAPB (R2986, Division of
Signal Transduction Therapy Unit (DSTT) at the Univer-
sity of Dundee) antibodies cross-linked to Protein A-
Sepharose Fast Flow beads (PAS beads, GE Healthcare
Life Sciences, Little Chalfont, UK). Uncoupled PAS beads
were used as a control. Endogenous FAF1 immunoprecip-
itation was performed using anti-FAF1 antibodies (S370D,
DSTT) and sheep IgG, without prior cross-linking to PAS
beads. Immunoprecipitation was performed at 4°C for
2 hr with rotation. The beads were washed with buffer A
and the proteins were eluted by incubating with 3×
Laemmli buffer for 10 min in Micro Bio-Spin columns
(BioRad, Hemel Hempstead, UK). Mouse brain tissue was
homogenized in buffer A using a Polytron (Kinematica,
Eschbach, Germany). The lysates were centrifuged for
10 min at 13,000 rpm, filtered using a 0.22 μm sieve and
centrifuged again for 10 min at 13,000 rpm. The superna-
tants were pre-cleared by incubation with uncoupled PAS
beads, three times for 20 min each, under rotation. All
steps were done at 4°C. For mass spectroscopy, the immu-
noprecipitation was performed as described with the
following changes: after washing with buffer A, the beads
were additionally washed with 100 mM Tris-HCl pH 8.5
and the bound proteins were eluted by incubating with
8 M urea in 100 mM Tris-HCl pH 8.5 for 15 min at 37°C.
The eluted proteins were reduced by incubation with
3 mM TCEP for 20 min and then with 11 mM iodoaceta-
mide for 15 min, both at room temperature. Samples were
pre-digested with 0.1 μg Lys-C (Roche) for 4 hr at 37°C,
then diluted and the buffer adjusted so the final digestion
buffer contained 2 M urea, 1 mM CaCl2 and 0.5 μg Tryp-
sin (Roche). Trypsin digestion was performed at 37°C for
16 hr. The digested peptides were acidified to pH < 3 using
1% TFA, purified using C18 Silica microspin columns
(The Nest Group, Southborough, USA), eluted in 0.1%
TFA, 50% ACN and stored dry at -80°C until mass
spectroscopy.
For SILAC immunoprecipitation, light- or heavy-la-
belled cells were treated with either MG132 or dimethyl
sulfoxide as a control. The cells were independently
lysed in buffer A and equal amounts of heavy and light
lysate were mixed before incubation with the appropri-
ate beads. The immunoprecipitation was performed as
described above. For lysine-ε-GlyGly peptide purifica-
tion, light-labelled cells were transfected with Flag-
VAPB and heavy-labelled cells with Flag-FAF1, both
treated with MG132 for 2 hr. The cells were independ-
ently lysed in buffer A, Flag-immunoprecipitated and
trypsin digested as described above. The digested pep-
tides were pooled together and the lysine-ε-GlyGly pep-
tides were immunoaffinity purified using the PTMScan
ubiquitin remnant motif (K-ε-GG) kit (Cell Signaling,
Leiden, The Netherlands; 5562) as described by Udeshi
et al. [37].
Indirect immunofluorescence microscopy
The cells were plated on cover glass (thickness No 1.5) for
24 hr, followed by Flag-ASNA1 plasmid transfection or
Flag-FAF1 tetracycline induction for 24 hr, and treated
with MG132 for 2 hr where indicated. Cells were then
fixed in 3.7% paraformaldehyde/PBS at room temperature
for 15 min, permeabilized in 0.2% Triton X-100/PBS for
5 min, and blocked in 3% FBS in PBS/0.05% Tween for
45 min. Antibodies diluted in 3% FBS in PBS/0.05%
Tween were sequentially added to the cells and incubated
for 1 hr at room temperature followed by three washes
with PBS/0.05% Tween. Cells were then incubated for
5 min with 4',6-diamidino-2-phenylindole (DAPI). Finally,
the samples were washed three times with PBS/0.05%
Tween, three times with PBS, and twice with water be-
fore mounting on microscope slides with Mowiol 4-88
(Polysciences, Eppelheim, Germany). Images were ob-
tained with a DeltaVision Spectris microscope (Applied
Precision, Issaquah, USA), using a CoolSNAP HQ camera
(Roper Scientific, Martinsried, Germany) and a 100× 1.4
NA objective (Olympus, Southend-on-Sea, UK). The Soft-
Worx software (Applied Precision) was used for image
acquisition and deconvolution.
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Recombinant protein expression and in vitro binding
assays
GST-fusion proteins were expressed in BL21 cells at
15°C for 16 hr upon induction with 0.1 mM isopropyl
β-D-1-thiogalactopyranoside. GST-TEV-VAPB proteins
were captured on GSH-Sepharose, washed and then
either eluted with 10 mM reduced glutathione or recov-
ered by incubating the resin with TEV-His6 protease,
which was subsequently removed by affinity chromatog-
raphy. To remove the GST tag, GST-TEV-Flag-FAF1
was cleaved using AcTEV protease (Invitrogen) over-
night at 4°C. Then 2 μg Flag-FAF1 was mixed with
0.5 μg of the indicated form of VAPB in a final volume
of 400 μl buffer B (50 mM HEPES/KOH, pH 7.5;
60 mM KOAc; 5 mM MgCl2; 5% glycerol; 0.1% Triton
X-100). BSA was added to control samples to reach the
same final protein concentration. The protein mixtures
were pre-incubated for 30 min at 4°C, then anti-Flag
beads (Sigma) were added and incubated for another
30 min at 4°C, under rotation. The beads were washed
and the bound proteins were eluted by incubation with
3× Laemmli buffer for 10 min at 70°C.
Mass spectrometry analysis
The dried peptides were resuspended in 20 μl 0.1% (v/v)
TFA and separated on a Dionex UltiMate 3000 LC sys-
tem (Thermo Scientific) using a 25 cm column packed
with 3 μm Magic C18 material (Michrom Bioresources,
Auburn, USA). Mass spectra were acquired on an LTQ
Orbitrap Velos mass spectrometer (Thermo Scientific)
operating in data-dependent mode. After conversion to
mzXML, the raw data were searched using Comet
against version 3.87 of the IPI human or mouse protein
database using static carboxamidomethylation of cyst-
eine residues, variable oxidation of methionine residues
and accounting for up to two missed tryptic cleavages.
For SILAC samples, variable modification of lysine and
arginine residues was also specified. The Trans-Proteomic
Pipeline was used to assign peptide and protein prob-
abilities and to filter results at a 1% false discovery rate.
Data from the anti di-glycine remnant antibody analysis
were searched using X!!TANDEM (v. 2010.12.01.1) with
the k-score plugin. Two sets of static modifications were
used: (1) carboxamidomethylation of cysteine and (2)
carboxamidomethylation of cysteine, SILAC heavy Lys
and Arg. Additionally, variable oxidation of methionine
and GlyGly modification of lysine residues were accounted
for.
Antibodies and chemicals
The following antibodies were used: mouse anti-Flag
M2 (Sigma, A8592), mouse anti-ubiquitin FK2 (Enzo,
PW8810), rabbit anti-ubiquitin (Dako, Ely, UK; Z0458),
mouse anti-p97 (Fitzgerald, North Acton, USA; 10R-
P104A), rabbit anti-VAPA (Epitomics, Burlingame, USA;
S1706), mouse anti-FAF1 (Abnova, Taipei City, Taiwan;
H00011124-A01), rabbit anti-FAF1 (courtesy of Millipore,
Billerica, USA), rabbit anti-GAPDH (Cell Signaling, 2118),
rabbit anti-RAB3GAP1 (Proteintech, Manchester, UK;
21663-1-AP), rabbit anti-RAB3GAP2 (Abgent, Maidenhead,
UK; AP9635B), rabbit anti-WDR44 (Bethyl, Montgomery,
USA; A301-441A), mouse anti-ASNA1 (Abnova, H00000439-
M03), rabbit anti-Syntaxin 1A (GeneTex, Irvine, USA;
GTX113559), rabbit anti-BAG6 (Cell Signaling, 8523S),
mouse anti-RPN2 (Abnova, H00006185-B01), rabbit anti-
CD147 (Abcam, Cambridge, UK; ab108317), Alexa Fluor®
488 goat anti-rabbit (Invitrogen, A11008) and Alexa Fluor®
594 chicken anti-mouse (Invitrogen, A21201). Anti-VAPA
(Epitomics, S1706) antibodies recognize both VAPA (upper
band) and VAPB (lower band) in human cell extracts. The
following antibodies were raised and affinity purified using
the appropriate antigen by the DSTT: sheep anti-FAF1
(S370D; antigen human FAF1, 1-650), rabbit anti-VAPB
(R2986 and R2987; antigen human VAPB, 1-210).
Additional files
Additional file 1: Table S1. Mass spectrometry analysis of Flag-FAF1
immunoprecipitates from human U2OS cells. Anti-Flag immunoprecipitates
from untransfected cells were used as a negative control. Protein coverage
and the share of spectrum IDs are indicated for each protein identified in
the immunoprecipitates.
Additional file 2: Figure S1. Ubiquitinated forms of VAPB are not
detectable in Flag-VAPB immunoprecipitates. U2OS cells expressing
Flag-VAPB from a tetracycline-inducible promoter were induced by
addition of 100 ng/ml tetracycline. Flag-VAPB was immunoprecipitated
after treatment with 10 μM MG132 for 1 or 2 hr, or 5 μM for 6 hr or from
untreated cells (0 hr). Two exposures of Flag-VAPB immunoblots are
shown. No ubiquitinated forms of Flag-VAPB can be detected with or
without proteasome inhibition, not even after a very long exposure.
Additional file 3: Table S2. Canonical FFAT proteins do not
accumulate in endogenous VAPB immunoprecipitates upon proteasome
inhibition.
Additional file 4: Table S3. SILAC mass spectrometry analysis of
endogenous VAPB immunoprecipitates from human U2OS cells. Light- or
heavy-labeled cells were treated with MG132 for 2 or 6 hr, as indicated.
Equal amounts of light- and heavy-labeled extracts were mixed and
endogenous VAPB was immunoprecipitated using specific antibodies.
The light/heavy SILAC ratios (L/H) determined by mass spectrometry are
indicated, as well as the protein coverage. L + MG indicates that the
light-labeled samples were treated with MG132. Proteins whose interaction
with VAPB is stimulated by proteasome inhibition accumulate in these
samples, resulting in L/H ratios higher than 1. H +MG indicates that the
heavy-labeled samples were treated with MG132. Protein accumulation in
the heavy-labeled samples results in L/H ratios lower than 1. The L/H for
proteins that are not affected by proteasome inhibition will be close to 1.
Additional file 5: Table S4. Mass spectrometry analysis of Flag-FAF1
immunoprecipitates from human U2OS cells treated with MG132 for 0, 2
or 6 hr as indicated. Anti-Flag immunoprecipitates from untransfected cells
were used as a negative control. Protein coverage and the share of spectrum
IDs are indicated for each protein identified in the immunoprecipitates.
Additional file 6: Table S5. Ubiquitinated targets of VAPB and FAF1
identified by mass spectrometry upon enrichment of ubiquitinated
peptides. A mixture of light-labeled Flag-VAPB and heavy-labeled Flag-FAF1
immunoprecipitates was analyzed by mass spectrometry after ubiquitinated
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peptide enrichment using antibodies specific to lysine-ε-GlyGly. The peptides
containing lysine residues with an additional MW due to the GlyGly modifi-
cation – 250.15 (heavy label) or 242.14 (light label) – are indicated for each
protein.
Additional file 7: Table S6. Mass spectrometry analysis of Flag-VAPA/B
immunoprecipitates from human U2OS cells. Anti-Flag immunoprecipitates
from untransfected cells were used as a negative control. Protein coverage
and the share of spectrum IDs are indicated for each protein identified in
the immunoprecipitates.
Additional file 8: Table S7. Mass spectrometry analysis of endogenous
VAPB immunoprecipitates from human HeLa cells. For the negative control
sample, cell extracts were incubated with uncoupled Protein A-beads and
the proteins retained on these beads were analyzed by mass spectrometry.
Protein coverage and the share of spectrum IDs are indicated for each protein
identified.
Additional file 9: Table S8. Mass spectrometry analysis of endogenous
VAPB immunoprecipitates from mouse brain. For the negative control
sample, brain extracts were incubated with uncoupled Protein A-beads and
the proteins retained on these beads were analyzed by mass spectrometry.
Protein coverage and the share of spectrum IDs are indicated for each
protein identified.
Additional file 10: Figure S2. STX1A and B are not FFAT-like proteins.
(A) Endogenous VAPB interacts with STX1A in mouse brain. (B) Alignment of
the sequences that resemble FFAT motifs in human STX1A and B.
(C) Flag-STX1A or B mutated for the two phenylalanine residues (F33A-F34A
and F32A-F33A, respectively) in the putative FFAT motifs interact with VAPB
similar to their WT counterparts. IP, immunoprecipitate; WT, wild type.
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